ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Brainstem Glioma
Interventions
DRUG

Thalidomide, etoposide, celecoxib

"Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.~Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day."

Trial Locations (1)

00029

Div of Hem/Onc and SCT, Children's Hospital, HUCH, Helsinki

All Listed Sponsors
collaborator

Kuopio University Hospital

OTHER

collaborator

Oulu University Hospital

OTHER

collaborator

Tampere University Hospital

OTHER

collaborator

Turku University Hospital

OTHER_GOV

lead

Helsinki University Central Hospital

OTHER

NCT01756989 - ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors | Biotech Hunter | Biotech Hunter